DANAHER CORP /DE/

Danaher Corp.

Diagnostics & Research Healthcare Washington, DC, United States DHR (NYQ)
Quarter: Q3 2025 Reported: July 22, 2025 Sentiment: Neutral

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Analysis Summary

This analysis is based on the provided text, which is an excerpt from Danaher's Form 8-K filing. The document primarily lists exhibits, including a press release titled 'Danaher Reports Second Quarter 2025 Results' (Exhibit 99.1) and the cover page formatted as Inline XBRL (Exhibit 104). Crucially, the provided text does not include the Q3 2025 earnings call transcript, detailed financial performance breakdown, strategic initiatives, business segment analysis, management commentary, forward guidance, competitive positioning, market trends, risk factors, or analyst Q&A highlights for Q3 2025. As such, a comprehensive analysis of Q3 2025 performance, including specific financial figures, strategic shifts, or future outlook, cannot be generated from the given information.

Key Highlights

  • The provided document is an 8-K filing.
  • It references a press release for Danaher's Q2 2025 results (Exhibit 99.1).
  • No Q3 2025 earnings call transcript or financial data is present in the provided text.
  • The document details exhibit information, including Inline XBRL formatting.

Financial Metrics

eps
YoY: N/A
revenue
N/A
YoY: N/A
guidance
net income
N/A
YoY: N/A

Stock Performance (90 Days)

Data through Dec 30, 2025
Layoff Events
Earnings Calls

Positive Signals

  • No confidence indicators can be extracted as the Q3 2025 earnings call transcript is not provided in the given text.

Risks & Concerns

  • No risk factors can be extracted as the Q3 2025 earnings call transcript is not provided in the given text.

Full Transcript

Recent Danaher Corp. News

Stock Price

$230.67
DHR· NYQ
0.02% day

Company Info

Industry
Diagnostics & Research
Sector
Healthcare
Headquarters
Washington, DC, United States
CEO
Mr. Rainer M. Blair
Employees
61,000
View Company Profile

Layoff Stats

Layoff Events
0
Total Affected
0

Recent Layoffs

No canonical layoff events recorded for this company.

Financials

Market Cap $165.14B
Revenue $24.27B
Profit Margin 14.4%
Cash $1.53B
Debt $18.16B